Dr. Yi Lin is a consultant in the division of hematology at Mayo Clinic, Rochester, MN. She received her medical degree from Northwestern University, and PhD from University of Minnesota in biomedical engineering. She completed medicine residency, hematology and medical oncology fellowship training with a clinical investigator track at Mayo Clinic. Her practice is in lymphoma and myeloma. She has an NIH-funded translational laboratory and clinical research program in tumor immunology, immunotherapy and biomarkers development, with a cell therapy focus. Her laboratory program focuses on myeloid cell dysregulation in cancer and targeting myeloid tumor crosstalk to overcome resistance to treatment. She is the PI and co-PI of multiple clinical trials testing novel dendritic cell vaccine combination immunotherapy and CAR-T therapy. As the chair of the Cell Therapy Cross-Disciplinary Group at Mayo Clinic Cancer Center, she also oversees the cancer cell therapy protocol portfolio and clinical practice for CAR-T treatments across all three Mayo sites in Minnesota, Arizona, and Florida.